Krakow, Poland, January 28, 2015 / B3C newswire / - Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, today announced that Pawel Przewiezlikowski, Chief Executive Officer of the company, will present at the upcoming 17th Annual BIO CEO & Investor Conference, which will take place on February 9 -10, at the Waldorf Astoria New York.
Mr Przewiezlikowski will present on Tuesday, February 10, at 11:00 a.m. in the Duke Windsor room, providing a corporate overview of the Company’s recent activities, including its transition to the Warsaw Stock Exchange Main Market, strategic plans concerned with the development of its R&D programs targeting PIM/FLT3 and CDK8 kinases in oncology, strategic discovery collaborations with Merck Serono, H3 Biomedicine and Felicitex Therapeutics, as well as the further growth of Selvita’s research service business.
A live audio webcast of the Selvita presentation will be accessible at: http://www.veracast.com/webcasts/bio/ceoinvestor2015/66212271148.cfm
The audio webcast will be archived shortly after the live event and will be available for 90 days through the Selvita website – http://www.selvita.com/investor-relations/educational-and-analytical-materials/presentations.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Its mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. BIO One-on-One PartneringTM provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.
About Selvita
Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 225 people, including 75 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2015. The most advanced programs at Selvita are SEL24, a pre-clinical PIM/FLT3 kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the Warsaw Stock Exchange in Poland (SLV).
Contact:
Natalia Baranowska
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 784 069 418